Skip to Content

Cabenuva (cabotegravir / rilpivirine) Disease Interactions

There are 6 disease interactions with Cabenuva (cabotegravir / rilpivirine):

Moderate

Cabotegravir (Includes Cabenuva) depression

Moderate Potential Hazard, Moderate plausibility. Applies to: Depression, Psychosis

Depressive disorders (including depressed mood, depression, altered mood, mood swings) have been reported with oral cabotegravir. Depressive disorders (including depressed mood, depression, major depression, altered mood, mood swings, dysphoria, negative thoughts, suicidal ideation/attempt) have been reported with IM cabotegravir-rilpivirine or the individual drug products. Patients with severe depressive symptoms should be evaluated promptly. Caution should be used in patients with a history of depression or other psychiatric conditions.

Moderate

Cabotegravir (Includes Cabenuva) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Hepatotoxicity has been reported in patients taking cabotegravir with or without known preexisting hepatic disease or identifiable risk factors. Patients with underlying liver disease or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations. Monitoring of liver chemistries is recommended and cabotegravir should be discontinued if hepatotoxicity is suspected. Cabotegravir has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.

Moderate

Cabotegravir (Includes Cabenuva) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No dose adjustment of IM or oral cabotegravir is required in patients with mild to moderate or mild to severe renal dysfunction, respectively. Cabotegravir has not been studied in patients with ESRD not on dialysis; caution is recommended. IM cabotegravir should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or ESRD.

Moderate

Rilpivirine (Includes Cabenuva) depression

Moderate Potential Hazard, Moderate plausibility. Applies to: Depression, Psychosis

Depressive symptoms including suicide ideation and suicide attempts have been reported with the use of rilpivirine. Patients should be monitored for the appearance of these symptoms and should seek medical evaluation immediately if severe depressive symptoms occur. Caution should be used in patients with a history of depression or other psychiatric conditions.

Moderate

Rilpivirine (Includes Cabenuva) liver impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Hepatic adverse events have been reported in patients taking rilpivirine. Patients with underlying hepatitis B or C virus infection or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations; a few cases of hepatic toxicity have been reported in patients without preexisting hepatic disease or other known risk factors. Appropriate laboratory testing before starting therapy and monitoring for hepatotoxicity during therapy are recommended in patients with underlying hepatic disease (e.g., hepatitis B or C virus infection) or in patients with marked baseline transaminase elevations. Rilpivirine has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.

Moderate

Rilpivirine (Includes Cabenuva) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Rilpivirine should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or end-stage renal disease, as drug concentrations can be increased due to alteration of drug absorption, distribution, and metabolism secondary to renal dysfunction. No dose adjustment is required in patients with mild or moderate renal dysfunction.

Cabenuva (cabotegravir / rilpivirine) drug interactions

There are 362 drug interactions with Cabenuva (cabotegravir / rilpivirine)

Cabenuva (cabotegravir / rilpivirine) alcohol/food interactions

There is 1 alcohol/food interaction with Cabenuva (cabotegravir / rilpivirine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.